Current Pharmacology Reports

, Volume 4, Issue 3, pp 182–192 | Cite as

Drug-Induced Liver Injury—Perspectives from Pathology

  • Shefali Chopra
  • Romil Saxena
Drug-induced Liver Injury (X Ma, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Drug-induced Liver Injury


Purpose of Review

Drug-induced liver injury (DILI) may be caused by prescription or over-the-counter medications, herbals and nutritional supplements, or environmental agents. This review provides an overview of (1) pathogenetic mechanisms and risk factors, (2) biochemical classification, (3) diagnostic approach, (4) role of liver biopsy, and (5) narratives on commoner agents that cause DILI.

Recent Findings

DILI is increasingly seen in contemporary practice due to increased usage of medications in general, introduction of newer agents for treatment of cancers and autoimmune diseases, and increasing consumption of herbals and nutritional supplements.


Drug-induced liver injury is a significant cause of liver disease worldwide. No clinical, biochemical, or histological feature is specific for the diagnosis of DILI, which can mimic every pattern of liver injury and is in the differential diagnosis of every patient with liver disease. The diagnosis of DILI relies on (1) establishing a temporal association between clinical disease and initiation of the suspected drug, followed in the majority of cases by clinical improvement and disease resolution on its withdrawal and (2) exclusion of competing causes of liver injury. Herbals and nutritional supplements are particularly interesting as these are generally regarded as “safe, natural” compounds by an increasingly health-conscious population. Establishing a temporal relationship is often challenging as the patient may be taking multiple supplements simultaneously and is usually unclear about timing of initiation and withdrawal of the agents. Additionally, these agents change in potency and composition depending on the harvest conditions of the constituent botanicals.


Histological patterns in drug-induced liver injury Role of liver biopsy in idiosyncratic drug-induced liver injury Idiosyncratic drug-induced liver injury Antineoplastic agents and drug-induced liver injury 


  1. 1.
    Fenkel JM, Navarro VJ. Herbal and dietary supplement-induced liver injury. Gastroenterol Hepatol (N Y). 2011;7(10):695–6.Google Scholar
  2. 2.
    Stournaras E, Tziomalos K. Herbal medicine-related hepatotoxicity. World J Hepatol. 2015 Sep 8;7(19):2189–93. Scholar
  3. 3.
    Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947–54.CrossRefPubMedGoogle Scholar
  4. 4.
    Bower WA, Johns M, Margolis HS, Williams IT, Bell BP. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007 Nov;102(11):2459–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Lasser KE, Allen PD, Woolhandler SJ, Himmelstein DU, Wolfe SM, Bor DH. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287(17):2215–20.CrossRefPubMedGoogle Scholar
  6. 6.
    Wysowski DK, Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165(12):1363–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Vuppalanchi R, Gotur R, Reddy KR, Fontana RJ, Ghabril M, Kosinski AS, et al. Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome. Clin Gastroenterol Hepatol. 2014;12(9):1550–5. Scholar
  8. 8.
    Williams R. Changing clinical patterns in acute liver failure. J Hepatol. 2003;39(4):660–1.CrossRefPubMedGoogle Scholar
  9. 9.
    Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl. 2004;10(8):1018–23.CrossRefPubMedGoogle Scholar
  10. 10.
    Hanje AJ, Chalasani N. How common is chronic liver disease from acute drug-induced liver injury? Gastroenterology. 2007;132(5):2067–8. discussion 2068-9CrossRefPubMedGoogle Scholar
  11. 11.
    Lefkowitch JH. The pathology of acute liver failure. Adv Anat Pathol. 2016;23(3):144–58. Scholar
  12. 12.
    Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. J Pharmacol Exp Ther. 1973;187(1):211–7.PubMedGoogle Scholar
  13. 13.
    Hinson JA, Roberts DW, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010;196:369–405. Scholar
  14. 14.
    Peterson RG, Rumack BH. Toxicity of acetaminophen overdose. JACEP. 1978;7(5):202–5.CrossRefPubMedGoogle Scholar
  15. 15.
    Williamson K, Wahl MS, Mycyk MB. Direct comparison of 20-hour IV, 36-hour oral, and 72-hour oral acetylcysteine for treatment of acute acetaminophen poisoning. Am J Ther. 2013;20(1):37–40. CrossRefPubMedGoogle Scholar
  16. 16.
    Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics. 2012;22(11):784–95. Scholar
  17. 17.
    Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology. 2008;47(6):2003–9. Scholar
  18. 18.
    Lammert C, Bjornsson E, Niklasson A, Chalasani N. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Hepatology. 2010;51(2):615–20. Scholar
  19. 19.
    Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology. 2013;58(1):388–96. Scholar
  20. 20.
    Ibáñez L, Pérez E, Vidal X, Laporte JR, Grup d’Estudi Multicènteric d’Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol. 2002;37(5):592–600.CrossRefPubMedGoogle Scholar
  21. 21.
    Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther. 2007;25(12):1411–21.CrossRefPubMedGoogle Scholar
  22. 22.
    Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 2002;22(2):145–55.CrossRefPubMedGoogle Scholar
  23. 23.
    Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 2009;29(4):337–47. CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Lucena MI, Andrade RJ, Fernández MC, Pachkoria K, Pelaez G, Durán JA, et al. Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity a prospective series from Spain. Hepatology. 2006;44(4):850–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Jinjuvadia K, Kwan W, Fontana RJ. Searching for a needle in a haystack: use of ICD-9-CM codes in drug-induced liver injury. Am J Gastroenterol. 2007;102(11):2437–43.CrossRefPubMedGoogle Scholar
  26. 26.
    Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005;129(2):512–21.CrossRefPubMedGoogle Scholar
  27. 27.
    Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44(1):33–60.CrossRefPubMedGoogle Scholar
  28. 28.
    Wynne HA, Cope LH, Mutch E, Rawlins MD, Woodhouse KW, James OF. The effect of age upon liver volume and apparent liver blood flow in healthy man. Hepatology. 1989;9(2):297–301.CrossRefPubMedGoogle Scholar
  29. 29.
    Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36(2):451–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Uetrecht J. Idiosyncratic drug reactions: current understanding. Annu Rev Pharmacol Toxicol. 2007;47:513–39.CrossRefPubMedGoogle Scholar
  31. 31.
    Uetrecht JP. New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol. 1999;12(5):387–95.CrossRefPubMedGoogle Scholar
  32. 32.
    Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol. 1995;23(Suppl 1):16–24.PubMedGoogle Scholar
  33. 33.
    Knowles SR, Uetrecht J, Shear NH. Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet. 2000;356(9241):1587–91.CrossRefPubMedGoogle Scholar
  34. 34.
    Lewis JH. The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin Drug Saf. 2002;1(2):159–72.CrossRefPubMedGoogle Scholar
  35. 35.
    Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology. 2004;126(5):1477–80.CrossRefPubMedGoogle Scholar
  36. 36.
    Stewart JD, Horvath R, Baruffini E, Ferrero I, Bulst S, Watkins PB, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology. 2010;52(5):1791–6. Scholar
  37. 37.
    Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev. 2012;44(1):116–26. Scholar
  38. 38.
    Berson A, Fréneaux E, Larrey D, Lepage V, Douay C, Mallet C, et al. Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J Hepatol. 1994;20(3):336–42.CrossRefPubMedGoogle Scholar
  39. 39.
    Andrade RJ, Lucena MI, Alonso A, García-Cortes M, García-Ruiz E, Benitez R. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 2004;39(6):1603–12.CrossRefPubMedGoogle Scholar
  40. 40.
    Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011;141(1):338–47. Scholar
  41. 41.
    Kleiner DE, Chalasani NP, Lee WM, Fontana RJ, Bonkovsky HL, Watkins PB. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2014;59(2):661–70. Scholar
  42. 42.
    Lucena MI, Camargo R, Andrade RJ, Perez-Sanchez CJ, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33(1):123–30.CrossRefPubMedGoogle Scholar
  43. 43.
    García-Cortés M, Lucena MI, Pachkoria K, Borraz Y, Hidalgo R, Andrade RJ, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury. Aliment Pharmacol Ther. 2008;27(9):780–9. Scholar
  44. 44.
    Navarro V, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363–73. Scholar
  45. 45.
    Andrade RJ, Lucena MI, Kaplowitz N, García-Muņoz B, Borraz Y, Pachkoria K, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology. 2006;44(6):1581–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Kleiner DE. The pathology of drug-induced liver injury. Semin Liver Dis. 2009;29(4):364–72. Scholar
  47. 47.
    Fontana RJ, Shakil AO, Greenson JK, Boyd I, Lee WM. Acute liver failure due to amoxicillin and amoxicillin/clavulanate. Dig Dis Sci. 2005;50(10):1785–90.CrossRefPubMedGoogle Scholar
  48. 48.
    Orman ES, Conjeevaram HS, Raj Vuppalanchi MD, Freston JW, Rochon J, Kleiner DE, et al. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011;9(6):517–523.e3. Scholar
  49. 49.
    Alqahtani SA, Kleiner DE, Ghabril M, Gu J, Hoofnagle JH, Rockey DC. Identification and characterization of cefazolin-induced liver injury. Clin Gastroenterol Hepatol. 2015;13(7):1328–1336.e2. Scholar
  50. 50.
    Björnsson ES, Gunnarsson BI, Gröndal G, Jonasson JG, Einarsdottir R, Ludviksson BR, et al. Risk of drug-induced liver injury from tumor necrosis factor antagonists. Clin Gastroenterol Hepatol. 2015;13(3):602–8. Scholar
  51. 51.
    Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013;11(5):558–564.e3. Scholar
  52. 52.
    Diallo A, Mekinian A, Boukari L, Mouas H, Zamy M, Nahon P. Severe hepatitis in a patient with adult-onset Still’s disease treated with anakinra. Rev Med Interne. 2013 Mar;34(3):168–70. Scholar
  53. 53.
    Alfreijat M, Habibi M, Bhatia P, Bhatia A. Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2013;52:1340–1.CrossRefGoogle Scholar
  54. 54.
    Shah RR, Morganroth J, Shah DR. Hepatotoxicity of tyrosine kinase inhibitors: clinical and regulatory perspectives. Drug Saf. 2013;36(7):491–503. Scholar
  55. 55.
    Al Sobhi E, Zahrani Z, Zevallos E, Zuraiki A. Imatinib-induced immune hepatitis: case report and literature review. Hematology. 2007;12(1):49–53.CrossRefPubMedGoogle Scholar
  56. 56.
    Seidel C, Fenner M, Länger F, Bantel H, Ganser A, Grünwald V. Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST). BMC Cancer. 2012;12:186. Scholar
  57. 57.
    Suzuki R, Kobayashi C, Sakai A, Fukushima H, Tagawa M, Satomi K, et al. Imatinib-induced severe hepatitis in a 9-year-old girl with Philadelphia chromosome-positive acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2015;37(6):e368–71. Scholar
  58. 58.
    Cross TJ, Bagot C, Portmann B, Wendon J, Gillett D. Imatinib mesylate as a cause of acute liver failure. Am J Hematol. 2006;81(3):189–92.CrossRefPubMedGoogle Scholar
  59. 59.
    James C, Trouette H, Marit G, Cony-Makhoul P, Mahon FX. Histological features of acute hepatitis after imatinib mesylate treatment. Leukemia. 2003;17:978–9.CrossRefPubMedGoogle Scholar
  60. 60.
    Kikuchi S, Muroi K, Takahashi S, Kawano-Yamamoto C, Takatoku M, Miyazato A, et al. Severe hepatitis and complete molecular response caused by Imatinib mesylate: possible association of its serum concentration and clinical outcomes. Leuk Lymphoma. 2004;45:2349–51.CrossRefPubMedGoogle Scholar
  61. 61.
    Lin NU, Sarantopoulos S, Stone JR, Galinsky I, Stone RM, Deangelo DJ, et al. Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003;102:3455–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Ohyashiki K, Kuriyama Y, Nakajima A, Tauchi T, Ito Y, Miyazawa H, et al. Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia. 2002;16:2160–1.CrossRefPubMedGoogle Scholar
  63. 63.
    Fairfax BP, Pratap S, Roberts IS, Collier J, Kaplan R, Meade AM, et al. Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma. BMC Cancer. 2012;12:590. Scholar
  64. 64.
    Herden U, Fischer L, Schäfer H, Nashan B, von Baehr V, Sterneck M. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient. Transplantation. 2010;90(1):98–9. Scholar
  65. 65.
    Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243(1):1–7.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Nordlinger B, Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol. 2006;24(31):4954–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Kandutsch S, Klinger M, Hacker S, Wrba F, Gruenberger B, Gruenberger T. Patterns of hepatotoxicity after chemotherapy for colorectal cancer liver metastases. Eur J Surg Oncol. 2008;34(11):1231–6. Scholar
  68. 68.
    Nalbantoglu IL, Tan BR Jr, Linehan DC, Gao F, Brunt EM. Histological features and severity of oxaliplatin-induced liver injury and clinical associations. J Dig Dis. 2014;15(10):553–60. Scholar
  69. 69.
    Vuppalanchi R, Saxena R, Storniolo AMV, Chalasani N. Pseudocirrhosis and liver failure in patients with metastatic breast cancer after treatment with palbociclib. Hepatology. 2017;65(5):1762–4. Scholar
  70. 70.
    Tallman MS, McDonald GB, DeLeve LD, Baer MR, Cook MN, Graepel GJ, et al. Incidence of sinusoidal obstruction syndrome following Mylotarg (gemtuzumab ozogamicin): a prospective observational study of 482 patients in routine clinical practice. Int J Hematol. 2013;97(4):456–64. Scholar
  71. 71.
    Giles FJ, Kantarjian HM, Kornblau SM, Thomas DA, Garcia-Manero G, Waddelow TA. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer. 2001;92(2):406–13.CrossRefPubMedGoogle Scholar
  72. 72.
    Gordon LI. Gemtuzumab ozogamicin (Mylotarg) and hepatic veno-occlusive disease: take two acetaminophen, and. Bone Marrow Transplant. 2001;28(9):811–2.CrossRefPubMedGoogle Scholar
  73. 73.
    Neumeister P, Eibl M, Zinke-Cerwenka W, Scarpatetti M, Sill H, Linkesch W. Hepatic veno-occlusive disease in two patients with relapsed acute myeloid leukemia treated with anti-CD33 calicheamicin(CMA-676) immunoconjugate. Ann Hematol. 2001;80:119–20.CrossRefPubMedGoogle Scholar
  74. 74.
    Force J, Saxena R, Schneider BP, Storniolo AM, Sledge GW Jr, Chalasani N, et al. Nodular regenerative hyperplasia after treatment with trastuzumab emtansine. J Clin Oncol. 2016;34(3):e9–12. Scholar
  75. 75.
    Kleiner DE, Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233–40.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pathology, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Department of PathologyIndiana University School of MedicineIndianapolisUSA

Personalised recommendations